ClinicalTrials.gg
CompletedNCT03644264Updated Jun 2, 2021

PA21 Safety and Efficacy in Adult Chinese Subjects

A Phase 3 interventional study of PA21 and sevelamer carbonate in Chronic Kidney Disease Requiring Chronic Dialysis and Hyperphosphatemia, sponsored by Vifor Fresenius Medical Care Renal Pharma. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-02.

Sponsored by Vifor Fresenius Medical Care Renal Pharma (part of CSL Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
286
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies in Hyperphosphatemia with a site in China — 6 open to participants now, 6 under way, 1 of them phase 3. Hyperphosphatemia · China.

Enrollment
2nd of 15
286 · median 158
Started
2018
the only one that year
Phase 3
7 of 18
1 open now
Registered
5th of 18
by date

Among the 18 studies in Hyperphosphatemia with a site in China, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2018, is one of 7 in phase 3, and was the 5th registered.

Hyperphosphatemia

173 studies on the registry are indexed under Hyperphosphatemia; 16 are open to participants now.

Browse Hyperphosphatemia studies →

Open to participants now

6 of the 18 studies in Hyperphosphatemia with a site in China are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 13 Hyperphosphatemia studies recruiting now, 11 (85%) set no upper age limit and 2 (15%) stop at 75 or younger; 4 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hyperphosphatemia with a site in China, or all of them as a file.
02

Study summary

This study evaluates the efficacy of PA21 in comparison with sevelamer carbonate (Renvela®) in lowering and maintaining serum phosphorus in adult Chinese subjects with CKD on dialysis after 12 weeks of treatment.

Read the detailed description

Primary Objective is to evaluate the efficacy of PA21 in comparison with sevelamer carbonate (Renvela®) in lowering and maintaining serum phosphorus in adult Chinese subjects with CKD on dialysis after 12 weeks of treatment. In addition , secondary objectives include evaluating the efficacy of PA21 and sevelamer carbonate over time as the percentage of subjects with serum phosphorus within the target range of 1.13 to 1.78 mmol/l (3.5 to 5.5 mg/dl) and to compare the safety and tolerability of PA21 versus sevelamer carbonate (Renvela®).

In total, 286 patients (143 patients to PA21 treatment and 143 patients to sevelamer carbonate treatment) will be randomised with a screening period: up to 4 weeks and a washout period of up to 3 weeks. Treatment period (total duration 12 weeks) will include a dose titration period and a maintenance period of an open-label, active-controlled comparison of PA21 versus sevelamer carbonate for 4 weeks. The primary efficacy assessment will be a non-inferiority assessment of the 2 groups of subjects at Week 12 in terms of serum phosphate lowering capability. There will be a follow-up period of 30 days after last dosing.

The investigational treatments will be a PA21 dose group of PA21 chewable tablets standardised to contain 500 mg of iron. PA21 contains approximately 20% m/m of elemental iron. All doses of PA21 are expressed in mg of iron. The Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted , provided a subject has been receiving that dose for a minimum of 2 weeks and for safety or tolerability reasons at any time. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day). The active control is sevelamer carbonate, Renvela®, tablets, containing 800 mg of sevelamer carbonate. The starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) are permitted, provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time. The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).

03

Conditions studied

  • Chronic Kidney Disease Requiring Chronic Dialysis
  • Hyperphosphatemia

Keywords

  • Chronic Kidney Disease
  • Hyperphosphatemia
  • Dialysis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Chinese subjects receiving either maintenance haemodialysis (HD) or peritoneal dialysis (PD) for at least 12 weeks prior to screening. No home HD or nocturnal HD (overnight stay at site) will be allowed
  2. Subjects with a history of hyperphosphataemia (HP).
  3. Subjects with serum phosphorus levels >5.5 mg/dl (>1.78 mmol/l) at screening or during the .
  4. Male and female adult subjects (aged ≥18 years at time of consent).
  5. Subjects with the ability to understand the requirements of the study and abide by the study restrictions, and who agree to return for the required assessments (in the Investigator's opinion).
  6. Subject (or legally acceptable representative) has provided the appropriate written . Subject must provide written informed consent before any study-specific procedures are performed including screening procedures.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with intact parathyroid hormone (iPTH) levels >800 ng/l (>800 pg/ml or 88 pmol/l) at screening. Subjects with iPTH >600 ng/l (>600 pg/ml or 66 pmol/l) at screening must be considered stable (in the Investigator's opinion).
  2. Subjects with planned or expected parathyroidectomy within the next 6 months (in the Investigator's opinion).
  3. Subjects on peritoneal dialysis (PD) with a history of peritonitis in the last 3 months or ≥3 episodes in the last 12 months.
  4. Subjects with serum total calcium >10.5 mg/dl (>2.6 mmol/l) or \<7.6 mg/dl (1.9 mmol/l) at screening.
  5. Subjects with:

    • Any history of major gastrointestinal (GI) surgery likely to influence the outcome of treatment with PBs
    • , active GI disorders (e.g., active peptic ulcer, Crohn's disease, colitis ulcerative, irritable bowel syndrome, intestinal motility disorder (symptomatic gastroparesis (during treatment or untreated), intestinal obstruction, moderate/severe constipation (including persistent symptoms with regular use of laxatives or enemas and limitations in activities of daily living), intestinal pseudo-obstruction, megacolon, mechanical obstruction)) or any GI disorders under medical treatment.
    • Clinically significant, active hepatic disorders or any hepatic disorder under medical treatment
  6. Subjects currently with (in the Investigator's opinion):

    • Swallowing difficulties/dysphagia
    • Estimated of less than 12 months
    • Anticipated renal transplantation during study participation
  7. Subjects with known seropositivity to or positive HIV test at screening.
  8. Subjects with active/current fulminant infections and/or virus ribonucleic acid positivity at screening.
  9. Subjects with a history of haemochromatosis or other iron accumulation disorders that might lead to iron overload.
  10. Subjects with serum ferritin >800 mcg/l (1,797.6 pmol/l) or transferrin saturation (TSAT) >50% at screening.
  11. Subjects with raised or aspartate aminotransferase >3 times the at screening.
  12. Subject is taking any prohibited medication(s) which cannot be stopped at least one week before study treatment start. Prohibited medications include: oral calcium supplements, any drugs/agents having a phosphate binding action that contain aluminium, magnesium or calcium (apart from hyperkalaemia drugs), phosphate binders in addition to sevelamer carbonate), nicotinamide, oral iron products, oral vitamins containing iron and other oral iron containing supplements (See Section 7.7).
  13. Subject has known and/or intolerance to any of the study products to be administered.
  14. Subject has previously been randomised into this study.
  15. Subject is currently enrolled in or has completed any other device or drug study \<30 days prior to screening, or is receiving other investigational agent(s).
  16. Subjects who are pregnant (e.g., positive human chorionic gonadotropin test) or breastfeeding.
  17. Subjects of , not using adequate precautions must agree to use a highly effective method of birth control during the study and for 1 month after the last dose of study medication.
  18. Subject has a history of drug or alcohol abuse within 2 years prior to screening.
  19. Subject has a significant medical conditions or anticipated need for major surgery during the study, which (in the Investigator's opinion), may be associated with increased risk to the subject, or may interfere with study assessments or outcomes, or the ability to provide or comply with study procedures.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
286 participants (actual)

Study arms

  • Experimental
    PA21 tablets containing 500 mg of iron

    PA21 chewable tablets standardised to contain 500 mg of iron. PA21 500 mg (iron) chewable tablet contains approximately 2.5 g PA21 drug substance (sucroferric oxyhydroxide). Starting dose will be 1,500 mg/day (3 tablets/day (1 tablet per meal)). Dose increases or decreases of 500 mg/day (1 tablet/day) are permitted. The maximum dose of PA21 will be 3,000 mg/day (6 x 500 mg tablets/day) and the minimum dose will be 1,000 mg/day (2 x 500 mg tablets/day).

    Drug: PA21

  • Active comparator
    Sevelamer carbonate: Renvela® tablets

    Starting dose will be 2.4 g/day (3 tablets/day). Dose increases or decreases of 2.4 g/day (3 tablets/day (1 tablet per meal)) The maximum dose of sevelamer carbonate will be 14.4 g/day (18 tablets/day) and the minimum dose will be 2.4 g/day (3 tablets/day).

    Drug: sevelamer carbonate

Interventions

  • DrugPA21

    sucroferric oxyhydroxide is a mixture of polynuclear iron(III)-oxyhydroxide (about 33% m/m), sucrose (about 30% m/m), and starches (about 28% m/m) and contains ≤10% m/m water.

    Also known as: sucroferric oxyhydroxide, Velphoro®

  • sevelamer carbonate tablets containing 800 mg of sevelamer carbonate.

    Also known as: Renvela®

06

What researchers measure

Primary outcomes

  1. Serum phosphorus (mmol/l )

    Change from baseline in serum phosphorus levels at Week 12: comparison between PA21 group and sevelamer carbonate group.

    Time frame: baseline and 12 weeks

Secondary outcomes

  1. Serum phosphorus (mmol/l )

    Serum phosphorus levels at each time point and change from baseline (BL)

    Time frame: baseline, weeks 1, 2, 4, 6, 8, 12

  2. Serum phosphorus (mmol/l)

    % of subjects with serum phosphorus within 1.13 to 1.78 mmol/l

    Time frame: baseline, weeks 1, 2, 4, 6, 8, 12

  3. Adverse events (AEs)

    Frequency of AEs determined by seriousness, severity and relatedness to study drugs

    Time frame: baseline, weeks 1, 2, 4, 6, 8, 12

  4. Diarrhoea.

    Frequency of AE of special interest - diarrhoea.

    Time frame: baseline, weeks 1, 2, 4, 6, 8, 12

  5. Withdrawals due to AEs

    Percentage of withdrawals due to AEs

    Time frame: baseline, weeks 1, 2, 4, 6, 8, 12

  6. Serum calcium (mmol/l)

    Serum total calcium levels at each time point and change from baseline

    Time frame: baseline, weeks 1, 2, 4, 6, 8, 12

  7. Hypercalcemia (mmol/l)

    Percentage of subjects that develop at least 1 episode of sustained hypercalcaemia (\>10.0 mg/dl; \>2.5 mmol/l) during study participation

    Time frame: baseline, weeks 1, 2, 4, 6, 8, 12

  8. Serum iPTH (pg/ml)

    Serum iPTH levels at specified time points and change from baseline

    Time frame: baseline, weeks 8, 12

  9. Serum iron (mcg/dl)

    Serum iPTH levels at specified time points and change from baseline

    Time frame: baseline, weeks 4, 8, 12

  10. Serum ferritin (mcg/l)

    Serum ferritin levels at specified time points and change from baseline

    Time frame: baseline, weeks 4, 8, 12

  11. Serum transferrin (mcg/dl)

    Serum transferrin measured at specified timepoints

    Time frame: baseline, weeks 4, 8, 12

  12. Transferrin saturation (TSAT) (%)

    TSAT measured at specified timepoints

    Time frame: baseline, weeks 4, 8, 12

07

Study locations

1 site
  • Southern Medical University Nanfang Hospital
    Guangzhou, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Aug 2020, 23 months.

Of 21 phase 3 interventional studies under Hyperphosphatemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 22. This study's 23 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2018
First posted
Aug 23, 2018
StartActual
Aug 31, 2018
Primary completionActual
Aug 21, 2020
CompletionActual
Aug 21, 2020
Last update
Jun 2, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 2, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03644264
Responsible party
Sponsor
First posted
Aug 23, 2018
Start date
Aug 31, 2018
Primary completion
Aug 21, 2020
Completion
Aug 21, 2020
Last update
Jun 2, 2021

Study contacts

Hou Fanfan, MD
principal investigator · Nanfang Hospital, Southern Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PA21

Start the discussion